CureVac (NASDAQ:CVAC) Shares Down 6.3%

CureVac (NASDAQ:CVAC) traded down 6.3% on Tuesday . The company traded as low as $2.95 and last traded at $2.95. 478,839 shares were traded during mid-day trading, a decline of 40% from the average session volume of 802,240 shares. The stock had previously closed at $3.15.

CureVac Trading Down 0.7 %

The company has a 50-day moving average of $3.41 and a 200-day moving average of $4.81. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.41 and a current ratio of 3.56.

Institutional Trading of CureVac

A number of institutional investors and hedge funds have recently modified their holdings of CVAC. Vontobel Holding Ltd. boosted its holdings in shares of CureVac by 3.8% in the 1st quarter. Vontobel Holding Ltd. now owns 19,411 shares of the company’s stock valued at $381,000 after buying an additional 702 shares during the period. Geode Capital Management LLC boosted its stake in CureVac by 0.7% in the first quarter. Geode Capital Management LLC now owns 167,202 shares of the company’s stock valued at $1,165,000 after acquiring an additional 1,188 shares during the period. Citigroup Inc. grew its holdings in shares of CureVac by 10.2% during the second quarter. Citigroup Inc. now owns 13,491 shares of the company’s stock valued at $141,000 after purchasing an additional 1,253 shares during the last quarter. Royal Bank of Canada raised its position in shares of CureVac by 13.0% during the 3rd quarter. Royal Bank of Canada now owns 11,119 shares of the company’s stock worth $87,000 after purchasing an additional 1,280 shares during the period. Finally, Marshall Wace LLP lifted its holdings in shares of CureVac by 0.5% in the 3rd quarter. Marshall Wace LLP now owns 333,819 shares of the company’s stock worth $2,629,000 after purchasing an additional 1,758 shares during the last quarter. 17.26% of the stock is owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.